Genomtec makes its debut on NewConnect

Medical technology company specializing in isothermal amplification of nucleic acids, applicable both in clinical diagnostics at the place of patient care - POCT, and rapid genetic testing, Genomtec SA, made its debut today at NewConnect market. Genomtec's flagship solution is the Genomtec ID mobile diagnostic system. The company is also a producer of ultra-fast diagnostic tests for SARS-CoV-2. From the very first moment, Genomtec shares were very popular among investors. The share price opened at PLN 16.60, or 51 percent more compared to the reference price.

“I believe that we are one of the few entities in the world so specialized in the technology of isothermal amplification of nucleic acids, which is the future of genetic diagnostics. The interest in the Genomtec ID device at international technology competitions confirms this. We are going according to the schedule and every month we are getting closer to completing the work on the system,” Miron Tokarski, founder, and president of Genomtec, said.

(WBJ)